Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12492811 | 0.82 | ALDH1A1 (0.53) | APLNRTP53KDM4EALDH1A1MEN1 | |
| SCHEMBL15511443 | 0.80 | HTR2A (0.47) | MTNR1AMTNR1BHTR2CHTR2BKDM4E | |
| SCHEMBL28970344 | 0.78 | APLNR (0.58) | APLNRTP53HTR2CKDM4EALDH1A1 | |
| SCHEMBL12492637 | 0.78 | HTR2A (0.46) | APLNRTP53HTR2CKDM4EALDH1A1 | |
| SCHEMBL28452492 | 0.76 | APLNR (0.63) | MTNR1AAPLNRTP53HTR2CALDH1A1 | |
| SCHEMBL12492806 | 0.76 | APLNR (0.52) | APLNRTP53KDM4EALDH1A1MEN1 | |
| SCHEMBL12494016 | 0.76 | ALDH1A1 (0.62) | APLNRTP53KDM4EALDH1A1MEN1 | |
| SCHEMBL12493456 | 0.76 | MMP8 (0.50) | APLNRTP53HTR2CMEN1KMT2A | |
| SCHEMBL12525710 | 0.76 | APLNR (0.49) | APLNRTP53HTR2CALDH1A1MEN1 | |
| SCHEMBL12492810 | 0.75 | ALDH1A1 (0.54) | APLNRTP53KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683701-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR THEIR PREPARATION, THEIR USAGE AS MEDICAMENT, MEDICAMENT CONTAINING SAME AND ITS USE | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| EP-2683701-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR THEIR PREPARATION, THEIR USAGE AS MEDICAMENT, MEDICAMENT CONTAINING SAME AND ITS USE | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| US-8846666-B2 | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846666-B2 | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20140066437-A1 | OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SANOFI (FR) | 2014-03-06 | — | — | US | disclosed |
| US-20140066437-A1 | OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SANOFI (FR) | 2014-03-06 | — | — | US | disclosed |
| WO-2012120058-A1 | OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066437-A1 | OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SLC5A2, SLC5A1, CYP11B2 | MTNR1A 2005/4885APLNR 3856/4885TP53 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.